Supreme Court Hears Bartlett, Will Resolve Liability Questions for “Design-Defect” of Generic Drugs

by Quinn Emanuel Urquhart & Sullivan, LLP

In March, the U.S. Supreme Court held oral argument in Mutual Pharmaceutical Co. v. Bartlett, concerning whether design-defect claims against generic drug companies are preempted by federal law. Although the case addresses liability only for generic manufacturers, brand-name drug companies could also be affected by the ruling. If the Court holds that claims against generic companies are preempted, then brand-name companies would be the only defendants left standing. And, as the only viable defendants, plaintiffs’ lawyers could try to find new ways to hold brand-name companies liable, even for injuries caused by generic drugs.

Bartlett is a follow-up to the Court’s landmark ruling in PLIVA, Inc. v. Mensing, __U.S. __131 S. Ct. 2567 (2011), which also addressed federal preemption of claims against generic drug companies. In Mensing, the Court held, in a 5-4 decision, that products-liability claims based on labeling deficiencies were preempted by federal law. The Court noted that because federal law requires generic drug companies to use the same labels as brand-name manufacturers, it would be impossible for a defendant to comply with a judgment, based on a state-law claim, requiring it to change or enhance label warnings. “Thus, it was impossible for the Manufacturers to comply with both their state-law duty to change the label and their federal law duty to keep the label the same.” Id. at 2578.

Relying on Mensing, various courts have since dismissed state-law personal injury claims against generic drug companies. But, in Bartlett—the case now on appeal to the Supreme Court—the First Circuit distinguished Mensing and held that a particular type of state-law claim could survive federal preemption.

The plaintiff, Karen Bartlett, suffered from a rare side effect that caused severe burns over most of her body when she took a generic version of a drug called sulindac. She sued the drug’s manufacturer and prevailed at trial on strict-liability design-defect claim. The jury awarded her $21 million in damages.

The generic manufacturer appealed to the First Circuit. The First Circuit affirmed the judgment, holding that Mensing did not control the outcome because it applied only to failure-to-warn claims, not to the design-defect claim asserted by Ms. Bartlett. The First Circuit acknowledged that, just like the requirement that generic drug companies use the same label as the brand-name version of the drug, federal law requires them to design their generics to have precisely the same chemical composition as brand-name drugs. And, a successful design-defect claim would require the generic manufacturer to change the drug’s composition—prohibited by federal law.

Despite the apparent similarity to Mensing, the First Circuit held that the generic manufacturer could avoid the contradictory requirements of state and federal law by refraining from manufacturing the drug. The First Circuit recognized its holding conflicted with decisions of other courts, saying “this issue needs a decisive answer from the only court that can supply it.” The Supreme Court granted certiorari.

The Supreme Court held oral argument on March 19. Based on the Justices’ questions, it is difficult to predict what the Court will decide. But commentators have correctly suggested Ms. Bartlett’s attorneys face an uphill battle in persuading the five Justices in the majority in Mensing that Bartlett is distinguishable. The fact that a generic manufacturer could simply stop manufacturing a drug to avoid preemption does not distinguish the case from Mensing. The defendant there also could have stopped manufacturing the drug, yet the Supreme Court still held the state-law claim was preempted. Moreover, the vast majority of lower courts have held that claims just like Ms. Bartlett’s are preempted.

Whatever the outcome, the opinion in Bartlett will have implications for brand-name manufacturers. Should the Supreme Court rule that the design-defect claim is preempted, then it will have effectively protected generic drug manufacturers from all products liability claims. Such a holding would leave brand-name manufacturers as the only viable defendants in pharmaceutical products liability cases. A decision in Bartlett is expected in June.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Quinn Emanuel Urquhart & Sullivan, LLP | Attorney Advertising

Written by:

Quinn Emanuel Urquhart & Sullivan, LLP

Quinn Emanuel Urquhart & Sullivan, LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at:

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.